These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 34427044)

  • 1. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
    Yalcin Kehribar D; Gunaydin S; Ozgen M
    Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab treatment in refractory vascular Behcet's disease: A single-center experience.
    Kehribar DY; Ozgen M
    Vascular; 2020 Dec; 28(6):829-833. PubMed ID: 32448079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurological Sequelae in Youngest Adult Behcet's Disease Patient on Infliximab.
    Sultan M; Khan A; Habib SS; Hayat M
    J Coll Physicians Surg Pak; 2020 Jul; 30(7):762-764. PubMed ID: 32811612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
    Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
    J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia.
    Houman MH; Bellakhal S; Ben Salem T; Hamzaoui A; Braham A; Lamloum M; Monia SK; Ben Ghorbel I
    Clin Neurol Neurosurg; 2013 Oct; 115(10):2015-8. PubMed ID: 23830180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.
    Hatemi I; Hatemi G; Pamuk ON; Erzin Y; Celik AF
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S129-37. PubMed ID: 26486925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and patterns of neurological involvement in Behcet's disease: a prospective study from Iraq.
    Al-Araji A; Sharquie K; Al-Rawi Z
    J Neurol Neurosurg Psychiatry; 2003 May; 74(5):608-13. PubMed ID: 12700303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging findings and outcome of neuro-Behçet's disease: the predictive factors.
    Farahangiz S; Sarhadi S; Safari A; Borhani-Haghighi A
    Int J Rheum Dis; 2012 Dec; 15(6):e142-9. PubMed ID: 23253242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
    Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
    Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience.
    Bolek EC; Sari A; Kilic L; Kalyoncu U; Kurne A; Oguz KK; Topcuoglu MA; Ertenli I; Karadag O
    Mult Scler Relat Disord; 2020 Feb; 38():101512. PubMed ID: 31733425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
    Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
    Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory neuro-Behçet treated by tocilizumab: a case report.
    Urbaniak P; Hasler P; Kretzschmar S
    Clin Exp Rheumatol; 2012; 30(3 Suppl 72):S73-5. PubMed ID: 23020826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
    Yoon DL; Kim YJ; Koo BS; Kim YG; Lee CK; Yoo B
    Int J Rheum Dis; 2014 May; 17(4):453-8. PubMed ID: 24506839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
    Bektaş M; Özer MD; Oğuz E
    Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
    Barešić M; Reihl M; Habek M; Vukojević N; Anić B
    Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological complications of Behçet's syndrome.
    Kidd D
    Curr Neurol Neurosci Rep; 2012 Dec; 12(6):675-9. PubMed ID: 23007835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenchymal Neuro-Behçet's disease or Comorbid Behçet's disease with multiple sclerosis: A discriminative analysis of a complex clinical entity.
    İsmayılov R; Talibov T; Gündüz T; Kürtüncü M
    Mult Scler Relat Disord; 2024 Jul; 87():105684. PubMed ID: 38788360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.